Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking

被引:52
作者
Chertok, Beata [1 ]
David, Allan E. [1 ,2 ]
Moffat, Bradford A. [3 ]
Yang, Victor C. [1 ,4 ]
机构
[1] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
[2] Ind Sci & Technol Network Inc, York, PA 17404 USA
[3] Univ Melbourne, Dept Radiol, Melbourne, Vic 3010, Australia
[4] Tianjin Univ, Tianjin Key Lab Modern Drug Delivery & High Effic, Tianjin 300072, Peoples R China
基金
澳大利亚国家健康与医学研究理事会;
关键词
Drug delivery; Cationic magnetic nanoparticles; Magnetic targeting; Brain tumors; Surface masking; NANOPARTICLES; DELIVERY; CHEMOTHERAPY; LIPOSOMES; HEPARIN; AGENTS; DNA;
D O I
10.1016/j.biomaterials.2009.08.040
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Cationic magnetic nanoparticles are attractive as potential vehicles for tumor drug delivery due to their favorable interactions with both the tumor milieu and the therapeutic cargo. However, systemic delivery of these nanoparticles to the tumor site is compromised by their rapid plasma clearance. We developed a simple method for in vivo protection of cationic nanocarriers, using non-covalent surface masking with a conjugate of low molecular weight heparin and polyethylene glycol. Surface masking resulted in a 11-fold increase in plasma AUC and a 2-fold increase in the magnetic capture of systemically injected nanoparticles in orthotopic rodent brain tumors. Overall, the described methodology could expand the prospective applications for cationic magnetic nanoparticles in magnetically mediated gene/drug delivery. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6780 / 6787
页数:8
相关论文
共 28 条
[1]   Magnetic drug targeting - Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment [J].
Alexiou, C ;
Jurgons, R ;
Schmid, RJ ;
Bergemann, C ;
Henke, J ;
Erhardt, W ;
Huenges, E ;
Parak, F .
JOURNAL OF DRUG TARGETING, 2003, 11 (03) :139-149
[2]   Magnetic ion-exchange nano- and microparticles for medical, biochemical and molecular biological applications [J].
Bergemann, C ;
Müller-Schulte, D ;
Oster, J ;
à Brassard, L ;
Lübbe, AS .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 1999, 194 (1-3) :45-52
[3]  
BLASBERG RG, 1986, SEMIN ONCOL, V13, P70
[4]   CYANOHYDRIDOBORATE ANION AS A SELECTIVE REDUCING AGENT [J].
BORCH, RF ;
BERNSTEIN, MD ;
DURST, HD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1971, 93 (12) :2897-+
[5]   Negative preclinical results with stealth® nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model [J].
Brigger, I ;
Morizet, J ;
Laudani, L ;
Aubert, G ;
Appel, M ;
Velasco, V ;
Terrier-Lacombe, MJ ;
Desmaële, D ;
d'Angelo, J ;
Couvreur, P ;
Vassal, G .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :29-40
[6]  
Campbell RB, 2002, CANCER RES, V62, P6831
[7]   Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors [J].
Chertok, Beata ;
Moffat, Bradford A. ;
David, Allan E. ;
Yu, Faquan ;
Bergemann, Christian ;
Ross, Brian D. ;
Yang, Victor C. .
BIOMATERIALS, 2008, 29 (04) :487-496
[8]  
Copley AL, 1943, J LAB CLIN MED, V28, P762
[9]   Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature [J].
Dandamudi, Suman ;
Campbell, Robert B. .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2007, 1768 (03) :427-438
[10]   Magnetic nanoparticles for drug delivery [J].
Dobson, J .
DRUG DEVELOPMENT RESEARCH, 2006, 67 (01) :55-60